161357-89-7

Usage

Uses

Used in Pharmaceutical Industry:
1-(Methanesulfonyl)-piperazine / 1-(Methanesulfonyl)-piperazine monohydrochloride is used as a building block for the synthesis of pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its versatility in organic synthesis allows for the creation of a wide range of pharmaceutical compounds with potential therapeutic benefits.
Used in Agrochemical Industry:
1-(Methanesulfonyl)-piperazine / 1-(Methanesulfonyl)-piperazine monohydrochloride is used as a building block for the synthesis of agrochemicals, such as pesticides and herbicides. Its potential applications in this industry contribute to the development of more effective and environmentally friendly agricultural products.
Used in Drug Discovery:
1-(Methanesulfonyl)-piperazine / 1-(Methanesulfonyl)-piperazine monohydrochloride is used as a reagent in drug discovery, aiding researchers in the identification and development of novel therapeutic agents. Its unique chemical properties make it a valuable tool in the search for new pharmaceutical compounds.
Used in Material Science:
1-(Methanesulfonyl)-piperazine / 1-(Methanesulfonyl)-piperazine monohydrochloride is used as an intermediate in the production of various chemical compounds, contributing to the advancement of material science. Its potential applications in this field may lead to the development of new materials with unique properties and uses.
Used in Research Applications:
1-(Methanesulfonyl)-piperazine / 1-(Methanesulfonyl)-piperazine monohydrochloride is used in research applications, providing scientists with a valuable tool for studying chemical reactions and processes. Its water-soluble monohydrochloride form makes it particularly useful in laboratory settings for a variety of research purposes.

Upstream product

• 164331-38-8 tert-butyl 4-(methylsulfonyl)piperazine-1-carboxylate 
• 50893-53-3 carbonochloridic acid 1-chloro-ethyl ester 
• 124-63-0 methanesulfonyl chloride 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1062188-94-6 N-[1-(3-Cyano-benzyl)-2-(4-methanesulfonyl-piperazin-1-yl)-2-oxo-ethyl]-4-methoxy-2,3,6-trimethyl-benzenesulfonamide 
• 161357-46-6 N^β-(2-naphthylsulfonyl)-3-cyano-L-phenylalanyl-4-(methylsulfonyl)piperazide 
• 1026519-59-4 N-[(S)-1-(3-Cyano-benzyl)-2-(4-methanesulfonyl-piperazin-1-yl)-2-oxo-ethyl]-C-((1S,4R)-7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-yl)-methanesulfonamide 
• 161357-49-9 2,2,5,7,8-Pentamethyl-chroman-6-sulfonic acid [(S)-1-(3-cyano-benzyl)-2-(4-methanesulfonyl-piperazin-1-yl)-2-oxo-ethyl]-amide 
• 885675-66-1 4-(2-chloro-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]-pyrimidin-4-yl)morpholine 
• 1155306-41-4 4-{4-chloro-6-[3-(4-methanesulfonylpiperazin-1-ylmethyl)phenyl]pyrimidin-2-yl}morpholine 
• 1250276-71-1 C₂₀H₂₁ClN₄O₃S 
• 1250276-72-2 C₂₀H₂₁FN₄O₃S 
• 1250276-74-4 C₂₀H₂₀F₂N₄O₃S 
• 1250276-75-5 C₂₀H₂₀ClFN₄O₃S 
• 1250276-66-4 C₂₁H₂₄N₄O₄S 
• 1250276-65-3 2-(4-methylsulfonylpiperazin-1-ylmethyl)-3-phenylquinazolin-4(3H)-one 

Relevant academic research and scientific papers

NOVEL BETULINIC SUBSTITUTED AMIDE DERIVATIVES AS HIV INHIBITORS

The present invention relates to novel betulinic substituted amide compounds of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y, Z1, Z2, Z3 and are Formula (II) as defined herein. The invention novel betulinic substituted amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.

Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies

Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed

Compounds with cardiac myosin activating function and pharmaceutical composition containing the same for treating or preventing heart failure

The present invention relates to a compound having a cardiotonic activating function and a pharmaceutical composition containing the same. The composition comprising the compound according to the present invention is effective in preventing or treating heart failure. In addition, the compound is represented by chemical formula 2 or is pharmaceutically acceptable salt thereof.COPYRIGHT KIPO 2016

Compounds with cardiac myosin activating function and pharmaceutical composition containing the same for treating or preventing heart failure

Disclosed are a compound having cardiotonic activity and a pharmaceutical composition containing the same, and the composition containing the compound, according to the present invention, is useful for preventing and treating heart failure.COPYRIGHT KIPO 2016

THERAPEUTIC AGENT FOR CEREBRAL INFARCTION

The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.

Synthesis of 2-(4-substitutedsulfonyl piperazin-l-yl-methyl)-3-aryl- quinazolin-4(3H)-one

Reaction of 2-(chloromethyl)-3-arylquinazolin-4(3H)-one 3 with N-BOC piperazine 4 in acetonitrile using K2CO3 and KI, followed by deprotection of BOC group in IPA HC1, gives 3-aryl-2-(piperazin-l-yl) quinazolin-4(3H)-one 6. The latte

2 -MORPHOLINOPYRIMIDINES AND THEIR USE AS PI3 KINASE INHIBITORS

Morpholino pyrimidines of formula (I): wherein R1 is selected from -Y-R6 and -NR4R5; R2 is a N-containing monocyclic heteroaryl group which is selected from pyridyl, isoxazolyl, imidazolyl, pyrazolyl, pyrrolyl, thiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, oxazolyl, furanyl, thienyl, triazolyl and tetrazolyl and which is unsubstituted or substituted by halo, -CN, -NR10R11, -OR10, -C(O)R10, -NR10C(O)R11, - N(C(O)R11)2, -NR10C(O)NR10R11, -SO2R10R11, -SO2NR10R11, -C(=O)OR10, -C(=O)NR10R11, halo-C1 -C6 alkyl and unsubstituted C1-C12 alkyl; R3 is selected from H, C1-C6 alkyl and C1-C6 alkoxy; Y is selected from a direct bond, -(CR2)m-, C2-C6 alkenylene, C2-C6 alkynylene, -(CR2)p-O-(CR2) t-, -(CR2)p-NR-(CR2) t, -(CR2)p-NR-(CR2)n-C(O)-, -(CR2)p-NR-C(O)- (CR2)n-, -(CR2)p-C(O)-NR-(CR2) t, -(CR2)p-C(O)-(CR2)n-NR-(CR2)t,- and -(CR2)p- C(O)-(CR2)n-; R6 is selected from an unsaturated 5- to 12-membered carbocyclic or heterocyclic ring, a saturated 5-, 6- or 7- membered N-containing heterocyclic group which is unsubstituted or substituted, C1-C6 alkyl, -NR2, -OR, -NR(CO)R and - C(O)NR2; R4 and R5, which are the same or different, are both C1-C6 alkyl which is unsubstituted or substituted, or R4 and R5 together form, with the nitrogen atom to which they are attached, a saturated 5-, 6- or 7- membered N-containing heterocyclic group which is unsubstituted or substituted; each R, which are the same or different when more than one is present in a given group, is independently H, C1-C6 alkyl which is unsubstituted or substituted or a 5- to 12-membered aryl or heteroaryl group which is unsubstituted or substituted; R10 and R11, which are the same or different, are independently selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl and C3-C8 cycloalkyl; n is 0 or an integer of 1 to 6; m is an integer of 1 to 6; p is 0 or an integer of 1 to 6; and t is 0 or an integer of 1 to 6, with the proviso that t is an integer of 2 to 6 when R6 is linked to Y through a constituent O or N atom of R6; and the pharmaceutically acceptable salts thereof, subject to various provisos, have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour, particularly that associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described